Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
```

LOGINID:ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * *
                     Welcome to STN International
NEWS
                 Web Page for STN Seminar Schedule - N. America
NEWS
      2 MAR 31
                 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                 IPC display formats
NEWS
      3
         MAR 31
                 CAS REGISTRY enhanced with additional experimental
                 spectra
NEWS
     4 MAR 31
                 CA/CAplus and CASREACT patent number format for U.S.
                 applications updated
NEWS 5 MAR 31
                 LPCI now available as a replacement to LDPCI
NEWS 6 MAR 31
                 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS
     7
        APR 04
                 STN AnaVist, Version 1, to be discontinued
NEWS 8 APR 15
                 WPIDS, WPINDEX, and WPIX enhanced with new
                 predefined hit display formats
NEWS 9 APR 28
                 EMBASE Controlled Term thesaurus enhanced
NEWS 10 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 11 MAY 30
                 INPAFAMDB now available on STN for patent family
                 searching
NEWS 12 MAY 30
                 DGENE, PCTGEN, and USGENE enhanced with new homology
                 sequence search option
NEWS 13
         JUN 06
                 EPFULL enhanced with 260,000 English abstracts
NEWS 14
         JUN 06
                 KOREAPAT updated with 41,000 documents
NEWS 15
         JUN 13
                 USPATFULL and USPAT2 updated with 11-character
                 patent numbers for U.S. applications
NEWS 16
         JUN 19 CAS REGISTRY includes selected substances from
                 web-based collections
NEWS 17
         JUN 25
                 CA/CAplus and USPAT databases updated with IPC
                 reclassification data
         JUN 30 AEROSPACE enhanced with more than 1 million U.S.
NEWS 18
                 patent records
         JUN 30
                 EMBASE, EMBAL, and LEMBASE updated with additional
NEWS 19
                 options to display authors and affiliated
                 organizations
NEWS 20
         JUN 30
                 STN on the Web enhanced with new STN AnaVist
                 Assistant and BLAST plug-in
NEWS 21
         JUN 30
                 STN AnaVist enhanced with database content from EPFULL
NEWS 22
         JUL 28
                 CA/CAplus patent coverage enhanced
NEWS 23
         JUL 28
                 EPFULL enhanced with additional legal status
                 information from the epoline Register
NEWS 24
         JUL 28
                 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25
         JUL 28
                 STN Viewer performance improved
NEWS 26
         AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
```

NEWS 27 AUG 13 CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998

NEWS 28 AUG 15 CAOLD to be discontinued on December 31, 2008

NEWS 29 AUG 15 CAplus currency for Korean patents enhanced

NEWS 30 AUG 25 CA/Caplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:46:13 ON 25 AUG 2008

=> file hcaplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

COST IN U.S. DOLLARS

FILE 'HCAPLUS' ENTERED AT 10:46:41 ON 25 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Aug 2008 VOL 149 ISS 9 FILE LAST UPDATED: 24 Aug 2008 (20080824/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification. => s RNA () polymerase () protein? 357529 RNA 30121 RNAS 363055 RNA (RNA OR RNAS) 226634 POLYMERASE 10671 POLYMERASES 228313 POLYMERASE (POLYMERASE OR POLYMERASES) 2610376 PROTEIN? L1229 RNA (W) POLYMERASE (W) PROTEIN? => s RdRp () protein? 776 RDRP 107 RDRPS 788 RDRP (RDRP OR RDRPS) 2610376 PROTEIN? 15 RDRP (W) PROTEIN? => s NS5B () protein? 1040 NS5B 2610376 PROTEIN? 154 NS5B (W) PROTEIN? L3 => s NSF () protein? 3863 NSF 20 NSFS 3870 NSF (NSF OR NSFS) 2610376 PROTEIN? 87 NSF (W) PROTEIN? L4=> s 11 or 12 or 13 or 14 482 L1 OR L2 OR L3 OR L4 => s AtRdRP1 () protein? 1 ATRDRP1 2610376 PROTEIN? 0 ATRDRP1 (W) PROTEIN? 1.6 => s 15 () inhibitor? 1117113 INHIBITOR? 7 L5 (W) INHIBITOR? 1.7 => s 17 and review/dt

=> d 18, ibib abs hitstr, 1

2176307 REVIEW/DT

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:819460 HCAPLUS

1 L7 AND REVIEW/DT

PUBLISHER:

DOCUMENT NUMBER: 149:94200

TITLE: A new method for HCV therapy: RNA-dependent RNA

polymerase inhibitor

AUTHOR(S): Zhang, Xiu-jie; Han, Xiao-feng; Ouyang, Hong-sheng CORPORATE SOURCE: College of Animal Husbandry and Veterinary Medicine, Jilin University, Changchun, 130062, Peop. Rep. China

Observation De Harman (2007) 130002, 160p. Ne

SOURCE: Shengming De Huaxue (2007), 27(3), 251-253

CODEN: SDHUEE; ISSN: 1000-1336 Shengming De Huaxue Bianjibu

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Chinese

AB A review. Hepatitis C is caused by infection of hepatitis C virus (HCV), a worldwide spread RNA virus; about 50% HCV infected cases would developed into chronic hepatitis, which has become a great problem for human health. NS5B protein, a non-structural protein (NS protein) of HCV with the function of RNA-dependent RNA polymerase (RdRp), is the core substance in HCV replication. Therefore, NS5B inhibitors can interrupt HCV replication and may play as anti-HCV drugs. Much work has been done on NS5B inhibitor development and some NS5B inhibitors have enter the clin. trial. Progress of NS5B inhibitor studies are reviewed with 14 refs.

=> s 15 and antagonist? 264649 ANTAGONIST?

L9 3 L5 AND ANTAGONIST?

=> s 19 and review/dt 2176307 REVIEW/DT

L10 0 L9 AND REVIEW/DT

=> d 19, ibib abs hitstr, 1-3

L9 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1064219 HCAPLUS

DOCUMENT NUMBER: 147:383999

TITLE: Detection of gene expression by specific cell types in mixed samples or tissues such as mouse thymus cortex

or medullary stromal cells using DGEM (differential

gene expression mapping)

INVENTOR(S): Petrie, Howard T.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 257pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIND		DATE		APPLICATION NO.						DATE		
WO 2007106507			A2	A2 20070920			WO 2007-US6363						20070314			
W:	ΑE,	AG,	AL,	ΑM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚM,	KN,
	KP,	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	MD,	MG,	MK,	MN,
	MW,	MX,	MY,	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,

RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006-782124P PRIORITY APPLN. INFO.: P 20060314 Differential gene expression mapping (DGEM) utilizes (1) laser capture microdissection or other methods of microdissection of the tissue regions of interest; (2) microarray screening of RNA isolated from the microdissected regions and anal. of purified individual cellular components from the tissue; and (3) computational profiling or subtraction to identify gene expression by specific cell types in situ. The method was applied to stromal cells from whole cortical and medullary regions of C57BL6 mouse thymus. As a result, DGEM, a reverse identification approach, solves previously insurmountable problems, as the lymphoid progenitors can be readily isolated, allowing fluctuations in receptor expression on lymphoid cells to be used to predict stratified stromal signals. An algorithmic approach can be used for calculating the expression profile of a tissue/sample of interest that consists of at least two types of cells. Specifically, the approach electronically subtracts the expression profile of one component of a sample from the expression profile of the total sample, thus revealing the profiles of the other component. To confirm the robustness of the DGEM procedure, the gene expression profiles from each sample of whole medulla, whole cortex, cortical thymocytes and medullary thymocytes was sorted based only on the expression data.

L9 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:67469 HCAPLUS

DOCUMENT NUMBER: 142:309250

TITLE: Inhibition of native hepatitis C virus replicase by

nucleotide and non-nucleoside inhibitors

AUTHOR(S): Ma, Han; Leveque, Vincent; De Witte, Anniek; Li,

Weixing; Hendricks, Than; Clausen, Saundra M.;

Cammack, Nick; Klumpp, Klaus

CORPORATE SOURCE: Roche Palo Alto LLC, Palo Alto, CA, 94304, USA

SOURCE: Virology (2005), 332(1), 8-15 CODEN: VIRLAX; ISSN: 0042-6822

PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A number of nucleotide and non-nucleoside inhibitors of HCV polymerase are currently under investigation as potential antiviral agents to treat HCV-infected patients. HCV polymerase is part of a replicase complex including the polymerase subunit NS5B together with other viral and host proteins and viral RNA. The RNA synthesis activity of the native replicase complex was inhibited by 3'-deoxy-CTP, a chain-terminating nucleotide analog, but not inhibited by non-nucleoside NS5B polymerase inhibitors of three different structural classes. The HCV replicase was also resistant to heparin, a broad-spectrum, RNA-competitive polymerase inhibitor. Prebinding of the recombinant NS5B protein with a RNA template rendered the polymerase largely resistant to the inhibition by heparin and the non-nucleoside inhibitors, but did not affect the inhibitory potency of 3'-deoxy-CTP. Therefore, the HCV

replicase showed a similar pattern of inhibitor sensitivity as compared to RNA-bound NS5B. These results suggest that the native HCV replicase complex represents a stable and productive polymerase-RNA complex. The allosteric non-nucleoside NS5B polymerase inhibitors are inactive against established HCV replicase but may function antagonistically with the formation of a productive enzyme-template complex.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:893420 HCAPLUS

DOCUMENT NUMBER: 136:112840

TITLE: Binding of the β 2 adrenergic receptor to

N-ethylmaleimide-sensitive factor regulates receptor

recycling

AUTHOR(S): Cong, Mei; Perry, Stephen J.; Hu, Liaoyuan A.; Hanson,

Phyllis I.; Claing, Audrey; Lefkowitz, Robert J. Howard Hughes Medical Institute, Departments of Medicine and Biochemistry, Duke University Medical

Center, Durham, NC, 27710, USA

SOURCE: Journal of Biological Chemistry (2001), 276(48),

45145-45152

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE: Journal LANGUAGE: English

CORPORATE SOURCE:

Following agonist stimulation, most G protein-coupled receptors become desensitized and are internalized, either to be degraded or recycled back to the cell surface. What dets. the fate of a specific receptor type after it is internalized is poorly understood. Here we show that the rapidly recycling β 2 adrenergic receptor (β 2AR) binds via a determinant including the last three amino acids in its carboxyl-terminal tail to the membrane fusion regulatory protein, N-ethylmaleimide-sensitive factor (NSF). This is documented by in vitro overlay assays and by cellular coimmunopptns. Receptors bearing mutations in any of the last three residues fail to interact with NSF. After stimulation with the agonist isoproterenol, a green fluorescent protein fusion of NSF colocalizes with the wild type β 2AR but not with a tail-mutated β 2AR. The β 2AR-NSF interaction is required for efficient internalization of the receptors and for their recycling to the cell surface. Mutations in the β 2AR tail that ablate NSF binding reduce the efficiency of receptor internalization upon agonist stimulation. subsequent treatment of cells with the antagonist propranolol, wild type receptors return to the cell surface, while tail-mutated receptors remain sequestered. Thus, the direct binding of the β 2AR to NSF demonstrates how, after internalization, the fate of a receptor is reliant on a specific interaction with a component of the cellular membrane-trafficking machinery.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:46:13 ON 25 AUG 2008)

```
FILE 'HCAPLUS' ENTERED AT 10:46:41 ON 25 AUG 2008
           229 S RNA () POLYMERASE () PROTEIN?
T.1
L2
            15 S RDRP () PROTEIN?
L3
           154 S NS5B () PROTEIN?
            87 S NSF () PROTEIN?
L4
L5
           482 S L1 OR L2 OR L3 OR L4
L6
              0 S ATRDRP1 () PROTEIN?
L7
              7 S L5 () INHIBITOR?
L8
             1 S L7 AND REVIEW/DT
L9
              3 S L5 AND ANTAGONIST?
              0 S L9 AND REVIEW/DT
L10
=> s 15 and virus
        393280 VIRUS
         82854 VIRUSES
        408184 VIRUS
                 (VIRUS OR VIRUSES)
L11
           273 L5 AND VIRUS
=> s 111 and review/dt
       2176307 REVIEW/DT
            9 L11 AND REVIEW/DT
=> d his
     (FILE 'HOME' ENTERED AT 10:46:13 ON 25 AUG 2008)
     FILE 'HCAPLUS' ENTERED AT 10:46:41 ON 25 AUG 2008
           229 S RNA () POLYMERASE () PROTEIN?
L1
L2
            15 S RDRP () PROTEIN?
L3
           154 S NS5B () PROTEIN?
            87 S NSF () PROTEIN?
L4
L5
            482 S L1 OR L2 OR L3 OR L4
L6
              0 S ATRDRP1 () PROTEIN?
L7
              7 S L5 () INHIBITOR?
L8
              1 S L7 AND REVIEW/DT
              3 S L5 AND ANTAGONIST?
L10
             0 S L9 AND REVIEW/DT
L11
            273 S L5 AND VIRUS
              9 S L11 AND REVIEW/DT
=> s 112 not 19
L13
            9 L12 NOT L9
\Rightarrow d 113, ibib abs hitstr, 1-9
L13 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:
                         2008:146559 HCAPLUS
                         148:577886
DOCUMENT NUMBER:
TITLE:
                         Protein expression system using Leishmania
AUTHOR(S):
                         Wu, Xiao-wen; Xu, Fan-hong; Zhu, Wei; Zhang, Guang-pu;
                         Guo, Sheng-qi
CORPORATE SOURCE:
                         First Research Office, Shanghai Institute of
                         Biological Products, Shanghai, 200052, Peop. Rep.
                         China
```

PUBLISHER:

Guoji Shengwu Zhipinxue Zazhi (2007), 30(4), 148-150 SOURCE:

CODEN: GSZZAK; ISSN: 1673-4211

Guoji Shengwu Zhipinxue Zazhi Bianjibu PUBLISHER:

DOCUMENT TYPE: Journal; General Review

Chinese LANGUAGE:

A review. This article reviews the protein expression system using Leishmania. The article discusses the gene expression from transcription by T7 RNA polymerase and RNA polymerase II. The article also discusses the expression of HBsAg antigen.

L13 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

2007:819460 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 149:94200

TITLE: A new method for HCV therapy: RNA-dependent RNA

polymerase inhibitor

Zhang, Xiu-jie; Han, Xiao-feng; Ouyang, Hong-sheng AUTHOR(S): CORPORATE SOURCE: College of Animal Husbandry and Veterinary Medicine, Jilin University, Changchun, 130062, Peop. Rep. China

Shengming De Huaxue (2007), 27(3), 251-253 SOURCE:

> CODEN: SDHUEE; ISSN: 1000-1336 Shengming De Huaxue Bianjibu

DOCUMENT TYPE: Journal; General Review LANGUAGE: Chinese

A review. Hepatitis C is caused by infection of hepatitis C virus (HCV), a worldwide spread RNA virus; about 50% HCV infected cases would developed into chronic hepatitis, which has become a great problem for human health. NS5B protein, a non-structural protein (NS protein) of HCV with the function of RNA-dependent RNA polymerase (RdRp), is the core substance in HCV replication. Therefore, NS5B inhibitors can interrupt HCV replication and may play as anti-HCV drugs. Much work has been done on NS5B inhibitor development and some NS5B inhibitors have enter the clin. trial. Progress of NS5B inhibitor studies are reviewed with 14 refs.

L13 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:741280 HCAPLUS

DOCUMENT NUMBER: 145:329946

TITLE: Nonstructural protein 5B of hepatitis C virus AUTHOR(S): Lee, Jong-Ho; Nam, In Young; Myung, Heejoon

CORPORATE SOURCE: Department of Bioscience and Biotechnology, Hankuk

University of Foreign Studies, Yongin, 449-791, S.

Korea

SOURCE: Molecules and Cells (2006), 21(3), 330-336

CODEN: MOCEEK; ISSN: 1016-8478

Korean Society for Molecular and Cellular Biology PUBLISHER:

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

A review. Since its identification in 1989, hepatitis C virus AB was the subject of extensive research. The biol. of the virus and the development of antiviral drugs are closely related. The RNA polymerase activity of nonstructural protein 5B was first demonstrated in 1996. NS5B is believed to localize to the perinuclear region, forming a replicase complex with other viral proteins. It has a typical polymerase structure with thumb, palm, and finger domains encircling the active site. A de novo replication initiation mechanism was suggested. To date, many small mol. inhibitors are known including nucleoside analogs,

non-nucleoside analogs, and pyrophosphate mimics. NS5B interacts with other viral proteins such as core, NS3, 4A, 4B, and 5A. The helicase activity of NS3 seems necessary for RNA strand unwinding during replication, with other nonstructural proteins performing modulatory roles. Cellular proteins interacting with NS5B include VAMP-associated proteins, heIF4AII, hPLIC1, nucleolin, PRK2, α -actinin, and p68 helicase. The interactions of NS5B with these proteins might play roles in cellular trafficking, signal transduction, and RNA polymerization, as well

as

the regulation of replication/translation processes.

REFERENCE COUNT: 99 THERE ARE 99 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:475491 HCAPLUS

DOCUMENT NUMBER: 141:65664

TITLE: Transcription and replication of influenza

virus genome

AUTHOR(S): Honda, Ayae; Ishihama, Akira

CORPORATE SOURCE: Mol. Biol. Div., Nippon inst. Biol. Sci., Japan SOURCE: Tanpakushitsu Kakusan Koso (2004), 49(8), 1204-1211

CODEN: TAKKAJ; ISSN: 0039-9450

PUBLISHER: Kyoritsu Shuppan

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review on the genome structure of influenza virus, its

peculiar transcription mechanism, function regulation by "cap effector", a

functional map of the viral RNA polymerase,

proteins involved in functional transformation of RNA polymerase,

and mols. determining the host factors.

L13 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:255241 HCAPLUS

DOCUMENT NUMBER: 141:67932

TITLE: Effects of genotypic variations on hepatitis C

virus nonstructural protein 5B structure and

activity

AUTHOR(S): Hong, Zhi; Ferrari, Eric B.; Skelton, Angela;

Wright-Minoque, Jacquelyn; Zhong, Weidong; Lesburg,

Charles A.

CORPORATE SOURCE: Department of Antiviral Therapy, Schering-Plough

Research Institute, Kenilworth, NJ, 07033-0539, USA

SOURCE: Frontiers in Viral Hepatitis (2003), 109-121.

Editor(s): Schinazi, Raymond F.; Sommadossi,

Jean-Pierre; Rice, Charles M. Elsevier: Amsterdam,

Neth.

CODEN: 69FEJF; ISBN: 0-444-50986-0

DOCUMENT TYPE: Conference; General Review

LANGUAGE: English

AB A review. Nonstructural protein 5B (NS5B) of hepatitis C virus (HCV) possesses an RNA-dependent RNA polymerase (RdRp) activity responsible for viral genome replication. It presents an excellent target for antiviral development. Recent studies revealed that removal of the C-terminal hydrophobic domain improved the solubility of NS5B to a level suitable for enzymic characterization and structural determination This hydrophobic C-terminal tail is highly conserved among all six genotypes of

HCV, indicating an important functional and structural role, presumably as a membrane anchor for the assembly of a replication complex. Similar hydrophobic domains were also identified in related viruses such as pestiviruses and GB viruses. Removal of these hydrophobic domains had a universal impact on enzyme solubility and resulted in production

of

soluble polymerases from all six HCV genotypes, as well as from pestiviruses and GB viruses. Biochem. characterization demonstrated that the activity of RdRps from different HCV genotypes/subtypes varied and lacked a clear correlation either to the response to combination therapy or to the plasma viremia levels. Structure-based surface variability anal. further identified highly conserved regions in the active site and predicted asym. distribution of important functionality and critical structural elements essential for replication.

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:509812 HCAPLUS

DOCUMENT NUMBER: 134:97543

TITLE: Biochemical and immunologic properties of the

nonstructural proteins of the hepatitis C virus: Implications for development of

antiviral agents and vaccines

AUTHOR(S): De Francesco, Raffaele; Neddermann, Petra; Tomel,

Licia; Steinkuhler, Christian; Gallinari, Paola;

Folgori, Antonella

CORPORATE SOURCE: Istituto di Richerche di Biologia, Molecolare, "P.

Angeletti, " Pomezia, Rome, Italy

SOURCE: Seminars in Liver Disease (2000), 20(1), 69-83

CODEN: SLDIEE; ISSN: 0272-8087 Thieme Medical Publishers, Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

PUBLISHER:

AB A review with 150 refs. Infection with the hepatitis C virus (HCV) is the major cause of non-A, non-B hepatitis worldwide. The viral genome, a pos.-sense, single-stranded, 9.6-kb long RNA mol., is translated into a single polyprotein of about 3,000 amino acids. The viral polyprotein is proteolytically processed to yield all the mature viral gene products. The genomic order of HCV has been determined to be C \rightarrow E1 \rightarrow E2 \rightarrow p7 \rightarrow NS2 \rightarrow NS3 \rightarrow NS4A \rightarrow NS4B \rightarrow NS5A \rightarrow NS5B. C, E1, and E2 are the virion structural proteins. Whereas the function of p7 is currently unknown, NS2

to NS5B are thought to be the nonstructural proteins. Generation of the mature nonstructural proteins relies on the activity of viral proteinases. Cleavage at the NS2-NS3 junction is accomplished by a metal-dependent autocatalytic proteinase encoded within NS2 and the N-terminus of NS3. The remaining downstream cleavages are effected by a serine proteinase contained also within the N-terminal region of NS3. NS3, in addition, contains an RNA helicase domain at its C-terminus. NS3 forms a heterodimeric complex with NS4A. The latter is a membrane protein that acts as a cofactor of the proteinase. Although no function has yet been attributed to NS4B, NS5A has been recently suggested to be involved in mediating the resistance of the HCV to the action of interferon. Finally, the NS5B protein has been shown to be the viral RNA-dependent RNA polymerase. This article reviews the current

understanding of the structure and the function of the various HCV nonstructural proteins with particular emphasis on their potential as targets for the development of novel antiviral agents and vaccines.

REFERENCE COUNT: THERE ARE 150 CITED REFERENCES AVAILABLE FOR 150 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:435447 HCAPLUS

DOCUMENT NUMBER: 127:146877

ORIGINAL REFERENCE NO.: 127:28297a,28300a

TITLE: The nonstructural proteins of the hepatitis C

virus. Structure and functions

AUTHOR(S): Neddermann, Petra; Tomei, Licia; Steinkuhler,

Christian; Gallinari, Paola; Tramontano, Anna; De

Francesco, Raffaele

Istituto Ricerche Biologia Molecolare "P. Angeletti", CORPORATE SOURCE:

Rome, I-00040, Italy

Biological Chemistry (1997), 378(6), 469-476 CODEN: BICHF3; ISSN: 1431-6730 SOURCE:

PUBLISHER: de Gruyter

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

A review is given with many refs. The hepatitis C virus is the major causative agent of nonA-nonB hepatitis worldwide. Although this virus cannot be cultivated in cell culture, several of its features were been elucidated. The viral genome is a single-stranded, 9.5kb long RNA mol. of pos. polarity. The viral genome is translated into a single polyprotein of about 3000 amino acids. The virally encoded polyprotein undergoes proteolytic processing by a combination of cellular and viral proteolytic enzymes in order to yield all the mature viral gene products. The gene order of HCV was C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B. The mature structural proteins, C, E1 and E2 were shown to arise from the viral polyprotein via proteolytic processing by host signal peptidases. Conversely, generation of the mature nonstructural proteins relies on the activity of viral proteases. Thus, cleavage at the NS2/NS3 junction is accomplished by a metal-dependent autoprotease encoded within NS2 and the N-terminus of NS3. The remaining cleavages downstream from this site are effected by a Ser protease contained within the N-terminal region of NS3. Besides the protease domain, NS3 also contains an RNA helicase domain at its C-terminus. NS3 forms a heterodimeric complex with NS4A. The latter is a membrane protein that acted as a cofactor of the protease. Whereas the NS5B protein was the viral RNA-dependent RNA polymerase, no function has yet been attributed to NS4B and NS5A. The latter is a cytoplasmic phosphoprotein and appears to be

involved in mediating the resistance of the hepatitis C virus to the action of interferon.

L13 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:29133 HCAPLUS

DOCUMENT NUMBER: 122:72750

ORIGINAL REFERENCE NO.: 122:13675a,13678a

TITLE: Structure, organization, and expression of hepatitis C

virus genome

AUTHOR(S): Fuke, Isao; Manabe, Sadao; Okayama, Hiroto CORPORATE SOURCE: Research Foundation Microbial Diseases Osaka University, Kanonji, 768, Japan

SOURCE: Asian Medical Journal (1994), 37(5), 240-5

CODEN: ASMJAB; ISSN: 0004-461X

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

A review with 11 refs. Hepatitis C virus (HCV) is the major AB causative agent of posttransfusion non-A, non-B hepatitis, which has long been a serious medical problem worldwide. Following the isolation part of the HCV genome by Choo et al., the entire genome of ten independent HCV strains has subsequently been cloned and their primary structures have been elucidated. Sequence anal. has suggested that HCV is related to both flaviviruses and pestiviruses. The authors recently constructed a recombinant vaccinia virus that carried the entire HCV polyprotein coding region under an appropriate promoter. After infection of Change liver cells with the recombinant virus, the entire HCV polyprotein was produced and processed into core, envelope, E2, NS1, and NS3 proteins, as well as unexpectedly small NS4, NS5a, and NS5b proteins due to further cleavage of NS5 and perhaps NS2. Mutation and coexpression of studies of NS3 indicated that production of the nonstructural proteins of HCV absolutely requires an NS3-encoded putative protease.

L13 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:647238 HCAPLUS

DOCUMENT NUMBER: 121:247238

ORIGINAL REFERENCE NO.: 121:44959a,44962a

TITLE: DNA replication in filamentous bacteriophage

AUTHOR(S): Higashitani, Atsushi; Higashitani, Nahoko; Horiuchi,

Kensuke

CORPORATE SOURCE: Dep. Microb. Genet., Natl. Inst. Genet., Mishima, 411,

Japan

SOURCE: Tanpakushitsu Kakusan Koso (1994), 39(13), 2189-97

CODEN: TAKKAJ; ISSN: 0039-9450

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review with 19 refs. Nucleotide sequence of primer RNA, interactions

between minus chain origin and DNA and RNA polymerase, protein binding to DNA, etc. were related to mechanisms of

initiation of replication of minus and plus DNA chains of filamentous

bacteriophage.